34.88 0.00 (0.00%)
After hours: 4:35PM EDT
|Bid||34.91 x 800|
|Ask||39.12 x 3200|
|Day's Range||34.30 - 35.24|
|52 Week Range||16.69 - 41.57|
|Beta (3Y Monthly)||2.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||53.57|
Medicines Company announced interim results Saturday from the ongoing Phase 2 ORION-3 study that is evaluating the efficacy, safety and tolerability of inclisiran 300 mg in patients with atherosclerotic cardiovascular disease and elevated LDL cholesterol. The results show a consistent lowering of LDL cholesterol by more than 50 percent, with an overall follow-up of up to three years. The results were presented as a late-breaking presentation at the National Lipid Association Scientific Sessions in Miami.
NEW YORK, May 20, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of The Medicines Company (MDCO). You may also contact Robert H. Lefkowitz, Esq. Purcell Julie & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types of corporate misconduct.
The Medicines Company (MDCO) today announced interim results from the ongoing ORION-3 open-label extension study (Group 1, n=290) which showed that twice-a-year dosing with inclisiran sodium 300 mg resulted in consistent lowering of low density lipoprotein cholesterol (LDL-C) by more than 50 percent with overall follow-up of up to three years. Inclisiran was well tolerated, and no material safety issues were observed in the study.
Anyone researching The Medicines Company (NASDAQ:MDCO) might want to consider the historical volatility of the share...
Medicines Co NASDAQ/NGS:MDCOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high Bearish sentimentShort interest | NegativeShort interest is extremely high for MDCO with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MDCO. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding MDCO are favorable, with net inflows of $2.85 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Biotech stocks saw a reversal in sentiment as the week saw an earnings deluge from small-, micro- and nano-cap biotechs and some M&A activity . Here are some key catalysts for the unfolding week that should ...
The Medicines Company (MDCO) will host a conference call and webcast for investors on Saturday, May 18, 2019, at 5:30 p.m. EDT. During the call, the Company’s management and clinical trial investigators will review interim results on the long-term safety and efficacy data of inclisiran from the ongoing ORION-3 study.
The Medicines Company announced that it will participate in the Bank of America Merrill Lynch 2019 Healthcare Conference on Tuesday, May 14, 2019, in Las Vegas. The Company is scheduled to present at 8:00 a.m.
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
The stock market is rallying to record levels right now. In fact the S&P 500 has now enjoyed its best start to the year in 32 years. That's quite an achievement. But for investors, it can mean that it's becoming increasingly challenging to find stocks that are still trading at attractive levels. Here we used the TipRanks Stock Screener to find stellar stocks that still offer plenty of upside potential ahead. That's by filtering for stocks that fit the following criteria: a 'Strong Buy' analyst consensus, upside potential of over 10% based on the average analyst price target, and a very high Smart Score. If you haven't seen it already, the Smart Score pulls together 8 data sets to create a powerful rating that unites all of TipRanks' unique stock insights. Let's see how this applies with these four top stock picks below: 1\. Valero Energy CorpTexas-based Valero Energy (VLO – Research Report) is the largest independent refiner in the world, with 14 refineries and total crude throughput capacity of nearly 2.4 million barrels per day. And as the Smart Score shows, VLO scores highly on multiple datapoints. These include a bullish outlook from analysts, bloggers and hedge funds, as well as positive news sentiment. That gives VLO the highest-possible Smart Score of '10'.Most notably, the company has 100% Street support right now, with RBC Capital’s Brad Heffern reiterating his buy rating on April 25. “1Q19 EPS of $0.34 was a strong result given the worst macro environment in several years, and was made more impressive by the fact that VLO is a merchant refiner” cheers the analyst.View VLO Price Target & Analyst Rating DetailIndeed, the 1Q19 refining macro environment was one of the roughest in memory, with VLO's blended indicator at its second-lowest level going back to 2012. “We are happy to move on from this quarter, as the macro has improved significantly… but it is reassuring to see VLO can still put up positive earnings in a very weak environment” writes Heffern.And even though Valero disappointed with only $36 million of share buybacks in the quarter, it should now to return to its traditionally strong capital return program. RNC, for example, is estimating that the company will return $330 million to shareholders in 2Q19. 2\. The Medicines CoThe Medicines Company (MDCO – Research Report) is an evolving biopharma that focuses on cardiovascular, infectious and intensive care medicine. Like Valero, MDCO is riding high when it comes to both the Smart Score and analyst ratings. View MDCO Smart Score BreakdownHowever what stands out about The Medicines Company is the sheer extent of the upside potential predicted by the Street. With shares currently trading at $32, the average analyst price target of $60 suggests upside of close to 88%. And in fact, one of the most bullish analysts is Chardan Capital’s Gbola Amusa. His new $90 price target works out at 181% upside potential from current price levels. Plus Amusa highlights MDCO as a Chardan Top Pick for 2019. The best part: as we can see here, Amusa is a top-rated analyst for his savvy stock picking skills. According to Amusa, investors should keep an eye on the late-stage development of MDCO’s twice-a-year cholesterol-lowering injection inclisiran. Ahead of 3Q19 pivotal readouts, MDCO will present interim phase II data on 18 May and on 27 May.“Given cost-efficient execution by MDCO on advancing towards multiple inclisiran clinical readouts in the coming months, including the pivotal phase III readout of inclisiran in 3Q19, we maintain our high-conviction Buy rating and increase our PT to $90 (from $85)” the analyst wrote on April 26.Note that Goldman Sachs analyst Paul Choi also upgraded MDCO from Hold to Buy ahead of the phase III data release. He also doubled his price target from $25 to $50. 3\. Smartsheet IncSoftware stock Smartsheet (SMAR – Research Report) is certainly worth a closer look right now. Shares have exploded 70% year-to-date, but the stock continues to offer attractive growth potential.Five-star Stephens analyst Dmitry Netis has a $55 price target on shares (30% upside potential). The analyst has just paid a visit to SMAR’s headquarters to get the low down from management. Post-meeting, he told investors “We reiterate our Overweight rating, as we increasingly have confidence in management's ability to scale revenues to a $1 billion revenue run rate within the next 4-6 years.”In particular, the analyst believes that Smartsheet's customer focus—along with years of iterations to develop an engaging user experience—is widening the competitive gap against both established industry players (MSFT, GOOG, TEAM, NOW) and fast-moving competitors (Asana, Wrike). “We continue to be impressed with the caliber of Smartsheet's management team and its product-focused, customer-first culture, which drives continued innovation and product development (~90% product roadmap is from customer feedback)” summed up Netis. Overall the stock boasts a ‘Strong Buy’ Street consensus, with a Smart Score of 9 reflecting positive activity from bloggers, hedge funds, investors and Very Bullish news sentiment. View SMAR Smart Score Breakdown 4\. Amazon Inc Last but not least comes A-grade mega-cap Amazon.com, Inc. (AMZN – Research Report). Not only does Amazon boast a Smart Score of 10, it also scores a record-breaking 36 recent buy ratings from the Street. View AMZN Price Target & Analyst Rating DetailOne of the many analysts singing AMZN’s praises is Goldman Sachs’ Heath Terry. Following solid earnings results, Terry ramped up his AMZN price target from $2,100 to $2,400. This means he sees shares surging a further 25% in the coming months. The five-star analyst explained: "We continue to believe AMZN represents the best risk/reward in Internet given the relatively early-stage shift of workloads to the cloud, the transition of traditional retail online, and share gains in its advertising business, the long-term benefits of each we believe the market continues to underestimate for Amazon".For the quarter, Amazon reported revenue in-line with the Street at $59.7 billion. That’s with operating Income of $4.42B coming in well ahead of RBC/Street, thanks to the Gross Margin upside and better than expected Fulfillment leverage. But the news that caught the eye of many consumers was the fact that Prime free shipping is going from 2 days to 1 day. “This IS Big News, if you believe in Shipping Elasticity, which we do. The faster you ship, the more people buy… This could be a key growth catalyst for Amazon for some time” enthused RBC Capital’s Mark Mahaney following the announcement. With this analysis it’s not surprising that AMZN boasts a Very Bullish news sentiment as the Smart Score demonstrates below:View AMZN Smart Score Breakdown Find ‘Strong Buy’ stocks that tick every box. Go to TipRanks’ Top Smart Score Stocks now. This tool pools together a customizable list of all the top-ranked stocks with a perfect ‘10’ score, enabling you to pinpoint the best stocks for your investing strategy.
The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.
On a per-share basis, the Parsippany, New Jersey-based company said it had a loss of 80 cents. Losses, adjusted for one-time gains and costs, were 62 cents per share. Medicines Co. shares have increased ...
$MDCO announces #Q12019 financial results and significant progress with #inclisiran clinical development program. Find audio webcast and replay @ https://mdco.co/nqdzt.
The Medicines Company will host a conference call and audio webcast on Thursday, April 25, 2019 at 8:30 a.m. EDT to discuss its first quarter 2019 financial results and operational developments.
Medicines Co. (MDCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on the same.
Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic porphyria.
Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.